These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26294714)

  • 1. Engineered T cells can fight malignant T cells.
    Stauss HJ
    Blood; 2015 Aug; 126(8):927-8. PubMed ID: 26294714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies.
    Mamonkin M; Rouce RH; Tashiro H; Brenner MK
    Blood; 2015 Aug; 126(8):983-92. PubMed ID: 26056165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Chen KH; Wada M; Pinz KG; Liu H; Lin KW; Jares A; Firor AE; Shuai X; Salman H; Golightly M; Lan F; Senzel L; Leung EL; Jiang X; Ma Y
    Leukemia; 2017 Oct; 31(10):2151-2160. PubMed ID: 28074066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA-Engineered CD5-CAR-γδT
    Zhu Z; Li H; Lu Q; Zhang Z; Li J; Wang Z; Yang N; Yu Z; Yang C; Chen Y; Lu H; Wang W; Niu T; Nie C; Tong A
    Adv Sci (Weinh); 2024 Sep; 11(35):e2400024. PubMed ID: 39013083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains.
    Dai Z; Mu W; Zhao Y; Jia X; Liu J; Wei Q; Tan T; Zhou J
    Mol Ther; 2021 Sep; 29(9):2707-2722. PubMed ID: 34274536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.
    Wada M; Zhang H; Fang L; Feng J; Tse CO; Zhang W; Chen Q; Sha S; Cao Y; Chen KH; Pinz KG; Chen X; Fan XX; Jiang X; Ma Y
    Stem Cell Rev Rep; 2020 Apr; 16(2):369-384. PubMed ID: 32008159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.
    Avanzi MP; Brentjens RJ
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1429-1437. PubMed ID: 29118234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exonal switch down-regulates the expression of CD5 on blasts of acute T cell leukaemia.
    Rai AK; Singh A; Saxena A; Seth T; Raina V; Mitra DK
    Clin Exp Immunol; 2017 Dec; 190(3):340-350. PubMed ID: 28752543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
    Shirasu N; Kuroki M
    Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
    Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
    Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
    Liu L; Sun M; Wang Z
    Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
    Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TCR Gene Therapy: Challenges, Opportunities, and Future Directions.
    Stauss HJ; Tran MGB
    Cells; 2020 Dec; 9(12):. PubMed ID: 33271744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
    Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
    PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New development in CAR-T cell therapy.
    Wang Z; Wu Z; Liu Y; Han W
    J Hematol Oncol; 2017 Feb; 10(1):53. PubMed ID: 28222796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
    Chen L; Qiao D; Wang J; Tian G; Wang M
    Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.